Abstract: A method for preparing a leukocyte preparation from a leukocyte fraction and a correspondingly prepared or obtainable leukocyte preparation and its use. The methods include: a) sedimenting the leukocyte fraction removing leukocyte supernatant from the sediment, wherein the leukocyte supernatant is collected or remains in a leukocyte container, b) sedimenting the leukocytes in the leukocyte container, c) washing the sediment in the leukocyte container with a saline solution, and d) resuspending the sediment in the leukocyte container in a storage solution.

Abstract: A method for preparing a leukocyte preparation from a leukocyte fraction and a correspondingly prepared or obtainable leukocyte preparation and its use. The method includes: a) sedimenting the leukocyte fraction removing leukocyte supernatant from the sediment, wherein the leukocyte supernatant is collected or remains in a leukocyte container, b) sedimenting the leukocytes in the leukocyte container, c) washing the sediment in the leukocyte container with a saline solution, and d) resuspending the sediment in the leukocyte container in a storage solution.

Abstract: A method for preparing a leukocyte preparation from a leukocyte fraction and a correspondingly prepared or obtainable leukocyte preparation and its use. The method includes: a) sedimenting the leukocyte fraction removing leukocyte supernatant from the sediment, wherein the leukocyte supernatant is collected or remains in a leukocyte container, b) sedimenting the leukocytes in the leukocyte container, c) washing the sediment in the leukocyte container with a saline solution, and d) resuspending the sediment in the leukocyte container in a storage solution.

Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4 ??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: This invention concerns a thermally stable glass composition, which comprises the following constituents in the following proportions by weight:______________________________________ SiO.sub.2 45 to 68% Al.sub.2 O.sub.3 0 to 20% ZrO.sub.2 0 to 20% B.sub.2 O.sub.3 0 to 10% Na.sub.2 O 2 to 12% K.sub.2 O 3.5 to 9% CaO 1 to 13% MgO 0 to 8% ______________________________________the sum of the contents of the oxides SiO.sub.2, Al.sub.2 O.sub.3 and ZrO.sub.2 remaining equal to or less than 70%, the sum of the oxides Al.sub.2 O.sub.3 and ZrO.sub.2 being equal to or greater than 2%, the sum of the alkaline oxides Na.sub.2 O and K.sub.2 O being equal to or greater than 8%, said composition comprising, if desired, the oxides BaO and/or SrO in proportions such that:11%.ltoreq.MgO+CaO--BaO+SrO>30%This glass composition may be used for the production of substrates for an emissive screen or for that of a fire-resistant pane.

Abstract: The invention relates to glass substrates intended for use as a support in data storage units, reinforced by surface ion exchanges and whose matrix comprises the constituents given hereinafter in the following weight proportions:______________________________________ SiO.sub.2 45-65% Al.sub.2 O.sub.3 0-20% B.sub.2 O.sub.3 0-5% Na.sub.2 O 4-12% K.sub.2 O 3.5-12% MgO 0-8% CaO 0-13% ZrO.sub.2 0-20% ______________________________________the sum of the oxides SiO.sub.2, Al.sub.2 O.sub.3 and ZrO.sub.2 remaining equal to or below 70%, said composition optionally incorporating the oxides BaO and/or SrO in proportions 11%.ltoreq.MgO+CaO+BaO+SrO.ltoreq.24% and the alkaline oxides are introduced in the following weight percentages 0.22%.ltoreq.Na.sub.2 O/Na.sub.2 O+K.sub.2 O.ltoreq.0.60.

Abstract: This invention concerns a thermally stable glass composition, which comprises the following constituents in the following proportions by weight:______________________________________ SiO.sub.2 45 to 68% Al.sub.2 O.sub.3 0 to 20% ZrO.sub.2 0 to 20% B.sub.2 O.sub.3 0 to 10% Na.sub.2 O 2 to 12% K.sub.2 O 3.5 to 9% CaO 1 to 13% MgO 0 to 8% ______________________________________the sum of the contents of the oxides SiO.sub.2, Al.sub.2 O.sub.3 and ZrO.sub.2 remaining equal to or less than 70%, the sum of the oxides Al.sub.2 O.sub.3 and ZrO.sub.2 being equal to or greater than 2%, the sum of the alkaline oxides Na.sub.2 O and K.sub.2 O being equal to or greater than 8%, said composition comprising, if desired, the oxides BaO and/or SrO in proportions such that:11%.ltoreq.MgO+CaO+BaO+SrO<30%This glass composition may be used for the production of substrates for an emissive screen or for that of a fire-resistant pane.

Abstract: A transparent substrate provided with a covering multi-layer stack of thin coatings of which at least one is a metal coating (5) having low emissivity characteristics in the infrared positioned between two layers of the multi-layer stack, which are formed of a dielectric material, said multi-layer stack having at least one wetting layer below the metal coating (5), which wetting layer is based on tantalum oxide or niobium oxide.